サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1379666

動物疼痛管理の世界市場 - 産業動向と予測（～2030年）

Global Veterinary Pain Management Market - Industry Trends and Forecast to 2030
出版日: | 発行: Data Bridge Market Research | ページ情報: 英文 516 Pages | 納期: お問合せ

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
動物疼痛管理の世界市場 - 産業動向と予測（～2030年）
出版日: 2023年09月01日
発行: Data Bridge Market Research
ページ情報: 英文 516 Pages
納期: お問合せ
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の動物疼痛管理の市場規模は、2022年の21億5,110万3,970米ドルから2030年までに32億8,727万8,560米ドルに達し、2023年～2030年の予測期間にCAGRで5.6%の成長が見込まれています。

当レポートでは、世界の動物疼痛管理市場について調査分析し、産業動向と予測、促進要因と抑制要因、企業情勢などの情報を提供しています。

目次

第1章 イントロダクション

第2章 市場セグメンテーション

第3章 エグゼクティブサマリー

第4章 重要考察

  • PESTEL分析
  • ポーターのファイブフォース分析
  • ブランドの収益の分析

第5章 市場の概要

  • 促進要因
    • ペット飼育の増加
    • 獣医学の進歩
    • ペットの疾患の発症の増加
    • 動物ケアを強化する政府プロジェクトの増加
  • 抑制要因
    • ペットの世話にかかる費用の増加
    • 厳格な規制ガイドライン
  • 機会
    • 動物疼痛管理に向けた研究開発活動と製品承認の増加
    • 従来にない治療アプローチの人気の高まり
    • 技術の進歩
  • 課題
    • 獣医師の限られた利用可能性
    • 薬剤への耐性

第6章 世界の動物疼痛管理市場：製品タイプ別

  • 概要
  • 鎮痛薬
    • 抗炎症薬（NSAIDs）
    • オピオイド
  • コルチコステロイド
    • デキサメタゾン
    • プレドニゾロン
    • プレドニン
    • その他
  • アルファ2アゴニスト

第7章 世界の動物疼痛管理市場：薬剤タイプ別

  • 概要
  • ブランド
  • ジェネリック

第8章 世界の動物疼痛管理市場：購入方式別

  • 概要
  • 処方ベース
  • OTC

第9章 世界の動物疼痛管理市場：動物タイプ別

  • 概要
  • コンパニオンアニマル
    • 犬
    • 馬
    • ネコ科
    • その他
  • 生産動物
    • 牛
    • 豚
    • 家禽
    • 魚
    • その他

第10章 世界の動物疼痛管理市場：疼痛原因別

  • 概要
  • 慢性疼痛
  • 急性疼痛
  • 術後疼痛
  • 歯痛

第11章 世界の動物疼痛管理市場：投与別

  • 概要
  • 固体
    • タブレット
    • 粉末
    • その他
  • 液体
    • 溶液
    • シロップ
    • サスペンション
    • その他
  • 半固体
    • ゲル
    • クリーム
    • その他

第12章 世界の動物疼痛管理市場：投与経路別

  • 概要
  • 非経口
  • 経口
  • 局所

第13章 世界の動物疼痛管理市場：エンドユーザー別

  • 概要
  • 動物病院
  • 動物クリニック
  • ペットショップ
  • 動物農場
  • 学術・研究機関
  • その他

第14章 世界の動物疼痛管理市場：地域別

  • 概要
  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • フランス
    • 英国
    • イタリア
    • スペイン
    • オランダ
    • ロシア
    • スイス
    • ポーランド
    • ベルギー
    • トルコ
    • スウェーデン
    • デンマーク
    • ノルウェー
    • フィンランド
    • その他の欧州
  • アジア太平洋
    • 中国
    • オーストラリア
    • インド
    • 日本
    • シンガポール
    • インドネシア
    • マレーシア
    • ニュージーランド
    • 韓国
    • ベトナム
    • タイ
    • フィリピン
    • 台湾
    • その他のアジア太平洋
  • 南米
    • ブラジル
    • アルゼンチン
    • その他の南米
  • 中東・アフリカ
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦
    • エジプト
    • イスラエル
    • クウェート
    • オマーン
    • カタール
    • バーレーン
    • その他の中東・アフリカ

第15章 世界の動物疼痛管理市場、企業情勢

  • 企業シェア分析：世界
  • 企業シェア分析：北米
  • 企業シェア分析：欧州
  • 企業シェア分析：アジア太平洋

第16章 SWOT分析

第17章 企業プロファイル

  • ZOETIS SERVICES LLC
  • ELANCO
  • MERCK & CO., INC.
  • BOEHRINGER INGELHEIM INTERNATIONAL GMBH
  • VETOQUINOL
  • BIMEDA, INC.
  • CEVA ANIMAL HEALTH, LLC
  • CHANELLE PHARMA
  • DECHRA PHARMACEUTICALS PLC
  • DURVET ANIMAL HEALTH PRODUCTS
  • INOVET (A SUBSIDIARY OF ORION GROUP)
  • NORBROOK
  • VIRBAC

第18章 アンケート

第19章 関連レポート

図表

LIST OF TABLES

  • TABLE 1 BRAND REVENUE ANALYSIS FOR VETERINARY PAIN MANAGEMENT MARKET 85
  • TABLE 2 NUMBER OF U.S. HOUSEHOLD-OWNED PET ANIMALS 88
  • TABLE 3 GLOBAL VETERINARY PAIN MANAGEMENT MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND) 96
  • TABLE 4 GLOBAL ANALGESICS IN VETERINARY PAIN MANAGEMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 96
  • TABLE 5 GLOBAL ANALGESICS IN VETERINARY PAIN MANAGEMENT MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND) 96
  • TABLE 6 GLOBAL ANTI- INFLAMMATORY (NSAIDS) IN VETERINARY PAIN MANAGEMENT MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND) 97
  • TABLE 7 GLOBAL OPIOIDS IN VETERINARY PAIN MANAGEMENT MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND) 98
  • TABLE 8 GLOBAL MU AGONISTS IN VETERINARY PAIN MANAGEMENT MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND) 98
  • TABLE 9 GLOBAL PARTIAL MU AGONISTS IN VETERINARY PAIN MANAGEMENT MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND) 99
  • TABLE 10 GLOBAL KAPPA AGONIST MU ANTAGONISTS IN VETERINARY PAIN MANAGEMENT MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND) 100
  • TABLE 11 GLOBAL CORTICOSTEROIDS IN VETERINARY PAIN MANAGEMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 101
  • TABLE 12 GLOBAL CORTICOSTEROIDS IN VETERINARY PAIN MANAGEMENT MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND) 101
  • TABLE 13 GLOBAL ALPHA-2 AGONISTS IN VETERINARY PAIN MANAGEMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 102
  • TABLE 14 GLOBAL VETERINARY PAIN MANAGEMENT MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND) 105
  • TABLE 15 GLOBAL BRANDED IN VETERINARY PAIN MANAGEMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 105
  • TABLE 16 GLOBAL GENERIC IN VETERINARY PAIN MANAGEMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 105
  • TABLE 17 GLOBAL VETERINARY PAIN MANAGEMENT MARKET, BY MODE OF PURCHASE, 2021-2030 (USD THOUSAND) 108
  • TABLE 18 GLOBAL PRESCRIPTION BASED IN VETERINARY PAIN MANAGEMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 108
  • TABLE 19 GLOBAL OTC IN VETERINARY PAIN MANAGEMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 108
  • TABLE 20 GLOBAL VETERINARY PAIN MANAGEMENT MARKET, BY ANIMAL TYPE, 2021-2030 (USD THOUSAND) 111
  • TABLE 21 GLOBAL COMPANION ANIMAL IN VETERINARY PAIN MANAGEMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 111
  • TABLE 22 GLOBAL COMPANION ANIMAL IN VETERINARY PAIN MANAGEMENT MARKET, BY ANIMAL TYPE, 2021-2030 (USD THOUSAND) 111
  • TABLE 23 GLOBAL PRODUCTION ANIMAL IN VETERINARY PAIN MANAGEMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 112
  • TABLE 24 GLOBAL PRODUCTION ANIMAL IN VETERINARY PAIN MANAGEMENT MARKET, BY ANIMAL TYPE, 2021-2030 (USD THOUSAND) 113
  • TABLE 25 GLOBAL VETERINARY PAIN MANAGEMENT MARKET, BY PAIN SOURCE, 2021-2030 (USD THOUSAND) 116
  • TABLE 26 GLOBAL CHRONIC PAIN IN VETERINARY PAIN MANAGEMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 116
  • TABLE 27 GLOBAL ACUTE PAIN IN VETERINARY PAIN MANAGEMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 117
  • TABLE 28 GLOBAL POST OPERATIVE PAIN IN VETERINARY PAIN MANAGEMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 117
  • TABLE 29 GLOBAL DENTAL PAIN IN VETERINARY PAIN MANAGEMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 118
  • TABLE 30 GLOBAL VETERINARY PAIN MANAGEMENT MARKET, BY DOSAGE, 2021-2030 (USD THOUSAND) 121
  • TABLE 31 GLOBAL SOLID IN VETERINARY PAIN MANAGEMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 121
  • TABLE 32 GLOBAL SOLID IN VETERINARY PAIN MANAGEMENT MARKET, BY DOSAGE, 2021-2030 (USD THOUSAND) 121
  • TABLE 33 GLOBAL LIQUID IN VETERINARY PAIN MANAGEMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 122
  • TABLE 34 GLOBAL LIQUID IN VETERINARY PAIN MANAGEMENT MARKET, BY DOSAGE, 2021-2030 (USD THOUSAND) 122
  • TABLE 35 GLOBAL SEMI SOLID IN VETERINARY PAIN MANAGEMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 123
  • TABLE 36 GLOBAL SEMI-SOLID IN VETERINARY PAIN MANAGEMENT MARKET, BY DOSAGE, 2021-2030 (USD THOUSAND) 123
  • TABLE 37 GLOBAL VETERINARY PAIN MANAGEMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 127
  • TABLE 38 GLOBAL PARENTERAL IN VETERINARY PAIN MANAGEMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 127
  • TABLE 39 GLOBAL ORAL IN VETERINARY PAIN MANAGEMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 128
  • TABLE 40 GLOBAL TOPICAL IN VETERINARY PAIN MANAGEMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 128
  • TABLE 41 GLOBAL VETERINARY PAIN MANAGEMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 131
  • TABLE 42 GLOBAL VETERINARY HOSPITALS IN VETERINARY PAIN MANAGEMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 131
  • TABLE 43 GLOBAL VETERINARY CLINICS IN VETERINARY PAIN MANAGEMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 132
  • TABLE 44 GLOBAL PET SHOPS IN VETERINARY PAIN MANAGEMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 132
  • TABLE 45 GLOBAL ANIMAL FARMS IN VETERINARY PAIN MANAGEMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 133
  • TABLE 46 GLOBAL ACADEMIC & RESEARCH INSTITUTES IN VETERINARY PAIN MANAGEMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 133
  • TABLE 47 GLOBAL OTHERS IN VETERINARY PAIN MANAGEMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 134
  • TABLE 48 GLOBAL VETERINARY PAIN MANAGEMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 139
  • TABLE 49 NORTH AMERICA VETERINARY PAIN MANAGEMENT MARKET, BY COUNTRY, 2021-2030 (USD THOUSAND) 140
  • TABLE 50 NORTH AMERICA VETERINARY PAIN MANAGEMENT MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND) 140
  • TABLE 51 NORTH AMERICA ANALGESICS IN VETERINARY PAIN MANAGEMENT MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND) 140
  • TABLE 52 NORTH AMERICA ANTI-INFLAMMATORY (NSAIDS) IN VETERINARY PAIN MANAGEMENT MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND) 141
  • TABLE 53 NORTH AMERICA OPIOIDS IN VETERINARY PAIN MANAGEMENT MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND) 141
  • TABLE 54 NORTH AMERICA MU AGONISTS IN VETERINARY PAIN MANAGEMENT MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND) 142
  • TABLE 55 NORTH AMERICA PARTIAL MU AGONIST IN VETERINARY PAIN MANAGEMENT MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND) 142
  • TABLE 56 NORTH AMERICA KAPPA AGONIST-MU ANTAGONIST IN VETERINARY PAIN MANAGEMENT MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND) 142
  • TABLE 57 NORTH AMERICA CORTECOSTERIODS IN VETERINARY PAIN MANAGEMENT MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND) 143
  • TABLE 58 NORTH AMERICA VETERINARY PAIN MANAGEMENT MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND) 143
  • TABLE 59 NORTH AMERICA VETERINARY PAIN MANAGEMENT MARKET, BY MODE OF PURCHASE, 2021-2030 (USD THOUSAND) 143
  • TABLE 60 NORTH AMERICA VETERINARY PAIN MANAGEMENT MARKET, BY ANIMAL TYPE, 2021-2030 (USD THOUSAND) 144
  • TABLE 61 NORTH AMERICA COMPANION ANIMAL IN VETERINARY PAIN MANAGEMENT MARKET, BY ANIMAL TYPE, 2021-2030 (USD THOUSAND) 144
  • TABLE 62 NORTH AMERICA PRODUCTION ANIMAL IN VETERINARY PAIN MANAGEMENT MARKET, BY ANIMAL TYPE, 2021-2030 (USD THOUSAND) 144
  • TABLE 63 NORTH AMERICA VETERINARY PAIN MANAGEMENT MARKET, BY PAIN SOURCE, 2021-2030 (USD THOUSAND) 145
  • TABLE 64 NORTH AMERICA VETERINARY PAIN MANAGEMENT MARKET, BY DOSAGE, 2021-2030 (USD THOUSAND) 145
  • TABLE 65 NORTH AMERICA SOLID IN VETERINARY PAIN MANAGEMENT MARKET, BY DOSAGE, 2021-2030 (USD THOUSAND) 145
  • TABLE 66 NORTH AMERICA LIQUID IN VETERINARY PAIN MANAGEMENT MARKET, BY DOSAGE, 2021-2030 (USD THOUSAND) 146
  • TABLE 67 NORTH AMERICA SEMI-SOLID IN VETERINARY PAIN MANAGEMENT MARKET, BY DOSAGE, 2021-2030 (USD THOUSAND) 146
  • TABLE 68 NORTH AMERICA VETERINARY PAIN MANAGEMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 146
  • TABLE 69 NORTH AMERICA VETERINARY PAIN MANAGEMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 147
  • TABLE 70 U.S. VETERINARY PAIN MANAGEMENT MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND) 148
  • TABLE 71 U.S. ANALGESICS IN VETERINARY PAIN MANAGEMENT MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND) 148
  • TABLE 72 U.S. ANTI-INFLAMMATORY (NSAIDS) IN VETERINARY PAIN MANAGEMENT MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND) 148
  • TABLE 73 U.S. OPIOIDS IN VETERINARY PAIN MANAGEMENT MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND) 149
  • TABLE 74 U.S. MU AGONISTS IN VETERINARY PAIN MANAGEMENT MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND) 149
  • TABLE 75 U.S. PARTIAL MU AGONIST IN VETERINARY PAIN MANAGEMENT MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND) 149
  • TABLE 76 U.S. KAPPA AGONIST-MU ANTAGONIST IN VETERINARY PAIN MANAGEMENT MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND) 150
  • TABLE 77 U.S. CORTECOSTERIODS IN VETERINARY PAIN MANAGEMENT MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND) 150
  • TABLE 78 U.S. VETERINARY PAIN MANAGEMENT MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND) 150
  • TABLE 79 U.S. VETERINARY PAIN MANAGEMENT MARKET, BY MODE OF PURCHASE, 2021-2030 (USD THOUSAND) 151
  • TABLE 80 U.S. VETERINARY PAIN MANAGEMENT MARKET, BY ANIMAL TYPE, 2021-2030 (USD THOUSAND) 151
  • TABLE 81 U.S. COMPANION ANIMAL IN VETERINARY PAIN MANAGEMENT MARKET, BY ANIMAL TYPE, 2021-2030 (USD THOUSAND) 151
  • TABLE 82 U.S. PRODUCTION ANIMAL IN VETERINARY PAIN MANAGEMENT MARKET, BY ANIMAL TYPE, 2021-2030 (USD THOUSAND) 152
  • TABLE 83 U.S. VETERINARY PAIN MANAGEMENT MARKET, BY PAIN SOURCE, 2021-2030 (USD THOUSAND) 152
  • TABLE 84 U.S. VETERINARY PAIN MANAGEMENT MARKET, BY DOSAGE, 2021-2030 (USD THOUSAND) 152
  • TABLE 85 U.S. SOLID IN VETERINARY PAIN MANAGEMENT MARKET, BY DOSAGE, 2021-2030 (USD THOUSAND) 153
  • TABLE 86 U.S. LIQUID IN VETERINARY PAIN MANAGEMENT MARKET, BY DOSAGE, 2021-2030 (USD THOUSAND) 153
  • TABLE 87 U.S. SEMI-SOLID IN VETERINARY PAIN MANAGEMENT MARKET, BY DOSAGE, 2021-2030 (USD THOUSAND) 153
  • TABLE 88 U.S. VETERINARY PAIN MANAGEMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 154
  • TABLE 89 U.S. VETERINARY PAIN MANAGEMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 154
  • TABLE 90 CANADA VETERINARY PAIN MANAGEMENT MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND) 155
  • TABLE 91 CANADA ANALGESICS IN VETERINARY PAIN MANAGEMENT MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND) 155
  • TABLE 92 CANADA ANTI-INFLAMMATORY (NSAIDS) IN VETERINARY PAIN MANAGEMENT MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND) 156
  • TABLE 93 CANADA OPIOIDS IN VETERINARY PAIN MANAGEMENT MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND) 156
  • TABLE 94 CANADA MU AGONISTS IN VETERINARY PAIN MANAGEMENT MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND) 157
  • TABLE 95 CANADA PARTIAL MU AGONIST IN VETERINARY PAIN MANAGEMENT MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND) 157
  • TABLE 96 CANADA KAPPA AGONIST-MU ANTAGONIST IN VETERINARY PAIN MANAGEMENT MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND) 157
  • TABLE 97 CANADA CORTECOSTERIODS IN VETERINARY PAIN MANAGEMENT MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND) 158
  • TABLE 98 CANADA VETERINARY PAIN MANAGEMENT MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND) 158
  • TABLE 99 CANADA VETERINARY PAIN MANAGEMENT MARKET, BY MODE OF PURCHASE, 2021-2030 (USD THOUSAND) 158
  • TABLE 100 CANADA VETERINARY PAIN MANAGEMENT MARKET, BY ANIMAL TYPE, 2021-2030 (USD THOUSAND) 159
  • TABLE 101 CANADA COMPANION ANIMAL IN VETERINARY PAIN MANAGEMENT MARKET, BY ANIMAL TYPE, 2021-2030 (USD THOUSAND) 159
  • TABLE 102 CANADA PRODUCTION ANIMAL IN VETERINARY PAIN MANAGEMENT MARKET, BY ANIMAL TYPE, 2021-2030 (USD THOUSAND) 159
  • TABLE 103 CANADA VETERINARY PAIN MANAGEMENT MARKET, BY PAIN SOURCE, 2021-2030 (USD THOUSAND) 160
  • TABLE 104 CANADA VETERINARY PAIN MANAGEMENT MARKET, BY DOSAGE, 2021-2030 (USD THOUSAND) 160
  • TABLE 105 CANADA SOLID IN VETERINARY PAIN MANAGEMENT MARKET, BY DOSAGE, 2021-2030 (USD THOUSAND) 160
  • TABLE 106 CANADA LIQUID IN VETERINARY PAIN MANAGEMENT MARKET, BY DOSAGE, 2021-2030 (USD THOUSAND) 161
  • TABLE 107 CANADA SEMI-SOLID IN VETERINARY PAIN MANAGEMENT MARKET, BY DOSAGE, 2021-2030 (USD THOUSAND) 161
  • TABLE 108 CANADA VETERINARY PAIN MANAGEMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 161
  • TABLE 109 CANADA VETERINARY PAIN MANAGEMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 162
  • TABLE 110 MEXICO VETERINARY PAIN MANAGEMENT MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND) 163
  • TABLE 111 MEXICO ANALGESICS IN VETERINARY PAIN MANAGEMENT MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND) 163
  • TABLE 112 MEXICO ANTI-INFLAMMATORY (NSAIDS) IN VETERINARY PAIN MANAGEMENT MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND) 163
  • TABLE 113 MEXICO OPIOIDS IN VETERINARY PAIN MANAGEMENT MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND) 164
  • TABLE 114 MEXICO MU AGONISTS IN VETERINARY PAIN MANAGEMENT MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND) 164
  • TABLE 115 MEXICO PARTIAL MU AGONIST IN VETERINARY PAIN MANAGEMENT MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND) 164
  • TABLE 116 MEXICO KAPPA AGONIST-MU ANTAGONIST IN VETERINARY PAIN MANAGEMENT MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND) 165
  • TABLE 117 MEXICO CORTECOSTERIODS IN VETERINARY PAIN MANAGEMENT MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND) 165
  • TABLE 118 MEXICO VETERINARY PAIN MANAGEMENT MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND) 165
  • TABLE 119 MEXICO VETERINARY PAIN MANAGEMENT MARKET, BY MODE OF PURCHASE, 2021-2030 (USD THOUSAND) 166
  • TABLE 120 MEXICO VETERINARY PAIN MANAGEMENT MARKET, BY ANIMAL TYPE, 2021-2030 (USD THOUSAND) 166
  • TABLE 121 MEXICO COMPANION ANIMAL IN VETERINARY PAIN MANAGEMENT MARKET, BY ANIMAL TYPE, 2021-2030 (USD THOUSAND) 166
  • TABLE 122 MEXICO PRODUCTION ANIMAL IN VETERINARY PAIN MANAGEMENT MARKET, BY ANIMAL TYPE, 2021-2030 (USD THOUSAND) 167
  • TABLE 123 MEXICO VETERINARY PAIN MANAGEMENT MARKET, BY PAIN SOURCE, 2021-2030 (USD THOUSAND) 167
  • TABLE 124 MEXICO VETERINARY PAIN MANAGEMENT MARKET, BY DOSAGE, 2021-2030 (USD THOUSAND) 168
  • TABLE 125 MEXICO SOLID IN VETERINARY PAIN MANAGEMENT MARKET, BY DOSAGE, 2021-2030 (USD THOUSAND) 168
  • TABLE 126 MEXICO LIQUID IN VETERINARY PAIN MANAGEMENT MARKET, BY DOSAGE, 2021-2030 (USD THOUSAND) 168
  • TABLE 127 MEXICO SEMI-SOLID IN VETERINARY PAIN MANAGEMENT MARKET, BY DOSAGE, 2021-2030 (USD THOUSAND) 169
  • TABLE 128 MEXICO VETERINARY PAIN MANAGEMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 169
  • TABLE 129 MEXICO VETERINARY PAIN MANAGEMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 169
  • TABLE 130 EUROPE VETERINARY PAIN MANAGEMENT MARKET, BY COUNTRY, 2021-2030 (USD THOUSAND) 170
  • TABLE 131 EUROPE VETERINARY PAIN MANAGEMENT MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND) 171
  • TABLE 132 EUROPE ANALGESICS IN VETERINARY PAIN MANAGEMENT MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND) 171
  • TABLE 133 EUROPE ANTI-INFLAMMATORY (NSAIDS) IN VETERINARY PAIN MANAGEMENT MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND) 171
  • TABLE 134 EUROPE OPIOIDS IN VETERINARY PAIN MANAGEMENT MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND) 172
  • TABLE 135 EUROPE MU AGONISTS IN VETERINARY PAIN MANAGEMENT MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND) 172
  • TABLE 136 EUROPE PARTIAL MU AGONIST IN VETERINARY PAIN MANAGEMENT MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND) 172
  • TABLE 137 EUROPE KAPPA AGONIST-MU ANTAGONIST IN VETERINARY PAIN MANAGEMENT MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND) 173
  • TABLE 138 EUROPE CORTECOSTERIODS IN VETERINARY PAIN MANAGEMENT MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND) 173
  • TABLE 139 EUROPE VETERINARY PAIN MANAGEMENT MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND) 173
  • TABLE 140 EUROPE VETERINARY PAIN MANAGEMENT MARKET, BY MODE OF PURCHASE, 2021-2030 (USD THOUSAND) 174
  • TABLE 141 EUROPE VETERINARY PAIN MANAGEMENT MARKET, BY ANIMAL TYPE, 2021-2030 (USD THOUSAND) 174
  • TABLE 142 EUROPE COMPANION ANIMAL IN VETERINARY PAIN MANAGEMENT MARKET, BY ANIMAL TYPE, 2021-2030 (USD THOUSAND) 174
  • TABLE 143 EUROPE PRODUCTION ANIMAL IN VETERINARY PAIN MANAGEMENT MARKET, BY ANIMAL TYPE, 2021-2030 (USD THOUSAND) 175
  • TABLE 144 EUROPE VETERINARY PAIN MANAGEMENT MARKET, BY PAIN SOURCE, 2021-2030 (USD THOUSAND) 175
  • TABLE 145 EUROPE VETERINARY PAIN MANAGEMENT MARKET, BY DOSAGE, 2021-2030 (USD THOUSAND) 176
  • TABLE 146 EUROPE SOLID IN VETERINARY PAIN MANAGEMENT MARKET, BY DOSAGE, 2021-2030 (USD THOUSAND) 176
  • TABLE 147 EUROPE LIQUID IN VETERINARY PAIN MANAGEMENT MARKET, BY DOSAGE, 2021-2030 (USD THOUSAND) 176
  • TABLE 148 EUROPE SEMI-SOLID IN VETERINARY PAIN MANAGEMENT MARKET, BY DOSAGE, 2021-2030 (USD THOUSAND) 177
  • TABLE 149 EUROPE VETERINARY PAIN MANAGEMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 177
  • TABLE 150 EUROPE VETERINARY PAIN MANAGEMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 177
  • TABLE 151 GERMANY VETERINARY PAIN MANAGEMENT MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND) 178
  • TABLE 152 GERMANY ANALGESICS IN VETERINARY PAIN MANAGEMENT MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND) 178
  • TABLE 153 GERMANY ANTI-INFLAMMATORY (NSAIDS) IN VETERINARY PAIN MANAGEMENT MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND) 178
  • TABLE 154 GERMANY OPIOIDS IN VETERINARY PAIN MANAGEMENT MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND) 179
  • TABLE 155 GERMANY MU AGONISTS IN VETERINARY PAIN MANAGEMENT MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND) 179
  • TABLE 156 GERMANY PARTIAL MU AGONIST IN VETERINARY PAIN MANAGEMENT MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND) 179
  • TABLE 157 GERMANY KAPPA AGONIST-MU ANTAGONIST IN VETERINARY PAIN MANAGEMENT MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND) 180
  • TABLE 158 GERMANY CORTECOSTERIODS IN VETERINARY PAIN MANAGEMENT MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND) 180
  • TABLE 159 GERMANY VETERINARY PAIN MANAGEMENT MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND) 180
  • TABLE 160 GERMANY VETERINARY PAIN MANAGEMENT MARKET, BY MODE OF PURCHASE, 2021-2030 (USD THOUSAND) 181
  • TABLE 161 GERMANY VETERINARY PAIN MANAGEMENT MARKET, BY ANIMAL TYPE, 2021-2030 (USD THOUSAND) 181
  • TABLE 162 GERMANY COMPANION ANIMAL IN VETERINARY PAIN MANAGEMENT MARKET, BY ANIMAL TYPE, 2021-2030 (USD THOUSAND) 181
  • TABLE 163 GERMANY PRODUCTION ANIMAL IN VETERINARY PAIN MANAGEMENT MARKET, BY ANIMAL TYPE, 2021-2030 (USD THOUSAND) 182
  • TABLE 164 GERMANY VETERINARY PAIN MANAGEMENT MARKET, BY PAIN SOURCE, 2021-2030 (USD THOUSAND) 182
  • TABLE 165 GERMANY VETERINARY PAIN MANAGEMENT MARKET, BY DOSAGE, 2021-2030 (USD THOUSAND) 182
  • TABLE 166 GERMANY SOLID IN VETERINARY PAIN MANAGEMENT MARKET, BY DOSAGE, 2021-2030 (USD THOUSAND) 183
  • TABLE 167 GERMANY LIQUID IN VETERINARY PAIN MANAGEMENT MARKET, BY DOSAGE, 2021-2030 (USD THOUSAND) 183
  • TABLE 168 GERMANY SEMI-SOLID IN VETERINARY PAIN MANAGEMENT MARKET, BY DOSAGE, 2021-2030 (USD THOUSAND) 183
  • TABLE 169 GERMANY VETERINARY PAIN MANAGEMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 184
  • TABLE 170 GERMANY VETERINARY PAIN MANAGEMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 184
  • TABLE 171 FRANCE VETERINARY PAIN MANAGEMENT MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND) 185
  • TABLE 172 FRANCE ANALGESICS IN VETERINARY PAIN MANAGEMENT MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND) 185
  • TABLE 173 FRANCE ANTI-INFLAMMATORY (NSAIDS) IN VETERINARY PAIN MANAGEMENT MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND) 185
  • TABLE 174 FRANCE OPIOIDS IN VETERINARY PAIN MANAGEMENT MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND) 186
  • TABLE 175 FRANCE MU AGONISTS IN VETERINARY PAIN MANAGEMENT MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND) 186
  • TABLE 176 FRANCE PARTIAL MU AGONIST IN VETERINARY PAIN MANAGEMENT MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND) 186
  • TABLE 177 FRANCE KAPPA AGONIST-MU ANTAGONIST IN VETERINARY PAIN MANAGEMENT MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND) 187
  • TABLE 178 FRANCE CORTECOSTERIODS IN VETERINARY PAIN MANAGEMENT MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND) 187
  • TABLE 179 FRANCE VETERINARY PAIN MANAGEMENT MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND) 187
  • TABLE 180 FRANCE VETERINARY PAIN MANAGEMENT MARKET, BY MODE OF PURCHASE, 2021-2030 (USD THOUSAND) 188
  • TABLE 181 FRANCE VETERINARY PAIN MANAGEMENT MARKET, BY ANIMAL TYPE, 2021-2030 (USD THOUSAND) 188
  • TABLE 182 FRANCE COMPANION ANIMAL IN VETERINARY PAIN MANAGEMENT MARKET, BY ANIMAL TYPE, 2021-2030 (USD THOUSAND) 188
  • TABLE 183 FRANCE PRODUCTION ANIMAL IN VETERINARY PAIN MANAGEMENT MARKET, BY ANIMAL TYPE, 2021-2030 (USD THOUSAND) 189
  • TABLE 184 FRANCE VETERINARY PAIN MANAGEMENT MARKET, BY PAIN SOURCE, 2021-2030 (USD THOUSAND) 189
  • TABLE 185 FRANCE VETERINARY PAIN MANAGEMENT MARKET, BY DOSAGE, 2021-2030 (USD THOUSAND) 190
  • TABLE 186 FRANCE SOLID IN VETERINARY PAIN MANAGEMENT MARKET, BY DOSAGE, 2021-2030 (USD THOUSAND) 190
  • TABLE 187 FRANCE LIQUID IN VETERINARY PAIN MANAGEMENT MARKET, BY DOSAGE, 2021-2030 (USD THOUSAND) 190
  • TABLE 188 FRANCE SEMI-SOLID IN VETERINARY PAIN MANAGEMENT MARKET, BY DOSAGE, 2021-2030 (USD THOUSAND) 191
  • TABLE 189 FRANCE VETERINARY PAIN MANAGEMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 191
  • TABLE 190 FRANCE VETERINARY PAIN MANAGEMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 191
  • TABLE 191 U.K. VETERINARY PAIN MANAGEMENT MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND) 192
  • TABLE 192 U.K. ANALGESICS IN VETERINARY PAIN MANAGEMENT MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND) 192
  • TABLE 193 U.K. ANTI-INFLAMMATORY (NSAIDS) IN VETERINARY PAIN MANAGEMENT MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND) 192
  • TABLE 194 U.K. OPIOIDS IN VETERINARY PAIN MANAGEMENT MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND) 193
  • TABLE 195 U.K. MU AGONISTS IN VETERINARY PAIN MANAGEMENT MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND) 193
  • TABLE 196 U.K. PARTIAL MU AGONIST IN VETERINARY PAIN MANAGEMENT MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND) 193
  • TABLE 197 U.K. KAPPA AGONIST-MU ANTAGONIST IN VETERINARY PAIN MANAGEMENT MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND) 194
  • TABLE 198 U.K. CORTECOSTERIODS IN VETERINARY PAIN MANAGEMENT MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND) 194
  • TABLE 199 U.K. VETERINARY PAIN MANAGEMENT MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND) 194
  • TABLE 200 U.K. VETERINARY PAIN MANAGEMENT MARKET, BY MODE OF PURCHASE, 2021-2030 (USD THOUSAND) 195
  • TABLE 201 U.K. VETERINARY PAIN MANAGEMENT MARKET, BY ANIMAL TYPE, 2021-2030 (USD THOUSAND) 195
  • TABLE 202 U.K. COMPANION ANIMAL IN VETERINARY PAIN MANAGEMENT MARKET, BY ANIMAL TYPE, 2021-2030 (USD THOUSAND) 195
  • TABLE 203 U.K. PRODUCTION ANIMAL IN VETERINARY PAIN MANAGEMENT MARKET, BY ANIMAL TYPE, 2021-2030 (USD THOUSAND) 196
  • TABLE 204 U.K. VETERINARY PAIN MANAGEMENT MARKET, BY PAIN SOURCE, 2021-2030 (USD THOUSAND) 196
  • TABLE 205 U.K. VETERINARY PAIN MANAGEMENT MARKET, BY DOSAGE, 2021-2030 (USD THOUSAND) 196
  • TABLE 206 U.K. SOLID IN VETERINARY PAIN MANAGEMENT MARKET, BY DOSAGE, 2021-2030 (USD THOUSAND) 197
  • TABLE 207 U.K. LIQUID IN VETERINARY PAIN MANAGEMENT MARKET, BY DOSAGE, 2021-2030 (USD THOUSAND) 197
  • TABLE 208 U.K. SEMI-SOLID IN VETERINARY PAIN MANAGEMENT MARKET, BY DOSAGE, 2021-2030 (USD THOUSAND) 197
  • TABLE 209 U.K. VETERINARY PAIN MANAGEMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 198
  • TABLE 210 U.K. VETERINARY PAIN MANAGEMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 198
  • TABLE 211 ITALY VETERINARY PAIN MANAGEMENT MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND) 199
  • TABLE 212 ITALY ANALGESICS IN VETERINARY PAIN MANAGEMENT MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND) 199
  • TABLE 213 ITALY ANTI-INFLAMMATORY (NSAIDS) IN VETERINARY PAIN MANAGEMENT MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND) 199
  • TABLE 214 ITALY OPIOIDS IN VETERINARY PAIN MANAGEMENT MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND) 200
  • TABLE 215 ITALY MU AGONISTS IN VETERINARY PAIN MANAGEMENT MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND) 200
  • TABLE 216 ITALY PARTIAL MU AGONIST IN VETERINARY PAIN MANAGEMENT MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND) 200
  • TABLE 217 ITALY KAPPA AGONIST-MU ANTAGONIST IN VETERINARY PAIN MANAGEMENT MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND) 201
  • TABLE 218 ITALY CORTECOSTERIODS IN VETERINARY PAIN MANAGEMENT MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND) 201
  • TABLE 219 ITALY VETERINARY PAIN MANAGEMENT MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND) 201
  • TABLE 220 ITALY VETERINARY PAIN MANAGEMENT MARKET, BY MODE OF PURCHASE, 2021-2030 (USD THOUSAND) 202
  • TABLE 221 ITALY VETERINARY PAIN MANAGEMENT MARKET, BY ANIMAL TYPE, 2021-2030 (USD THOUSAND) 202
  • TABLE 222 ITALY COMPANION ANIMAL IN VETERINARY PAIN MANAGEMENT MARKET, BY ANIMAL TYPE, 2021-2030 (USD THOUSAND) 202
  • TABLE 223 ITALY PRODUCTION ANIMAL IN VETERINARY PAIN MANAGEMENT MARKET, BY ANIMAL TYPE, 2021-2030 (USD THOUSAND) 203
  • TABLE 224 ITALY VETERINARY PAIN MANAGEMENT MARKET, BY PAIN SOURCE, 2021-2030 (USD THOUSAND) 203
  • TABLE 225 ITALY VETERINARY PAIN MANAGEMENT MARKET, BY DOSAGE, 2021-2030 (USD THOUSAND) 203
  • TABLE 226 ITALY SOLID IN VETERINARY PAIN MANAGEMENT MARKET, BY DOSAGE, 2021-2030 (USD THOUSAND) 204
  • TABLE 227 ITALY LIQUID IN VETERINARY PAIN MANAGEMENT MARKET, BY DOSAGE, 2021-2030 (USD THOUSAND) 204
  • TABLE 228 ITALY SEMI-SOLID IN VETERINARY PAIN MANAGEMENT MARKET, BY DOSAGE, 2021-2030 (USD THOUSAND) 204
  • TABLE 229 ITALY VETERINARY PAIN MANAGEMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 205
  • TABLE 230 ITALY VETERINARY PAIN MANAGEMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 205
  • TABLE 231 SPAIN VETERINARY PAIN MANAGEMENT MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND) 206
  • TABLE 232 SPAIN ANALGESICS IN VETERINARY PAIN MANAGEMENT MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND) 206
  • TABLE 233 SPAIN ANTI-INFLAMMATORY (NSAIDS) IN VETERINARY PAIN MANAGEMENT MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND) 206
  • TABLE 234 SPAIN OPIOIDS IN VETERINARY PAIN MANAGEMENT MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND) 207
  • TABLE 235 SPAIN MU AGONISTS IN VETERINARY PAIN MANAGEMENT MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND) 207
  • TABLE 236 SPAIN PARTIAL MU AGONIST IN VETERINARY PAIN MANAGEMENT MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND) 207
  • TABLE 237 SPAIN KAPPA AGONIST-MU ANTAGONIST IN VETERINARY PAIN MANAGEMENT MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND) 208
  • TABLE 238 SPAIN CORTECOSTERIODS IN VETERINARY PAIN MANAGEMENT MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND) 208
  • TABLE 239 SPAIN VETERINARY PAIN MANAGEMENT MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND) 208
  • TABLE 240 SPAIN VETERINARY PAIN MANAGEMENT MARKET, BY MODE OF PURCHASE, 2021-2030 (USD THOUSAND) 209
  • TABLE 241 SPAIN VETERINARY PAIN MANAGEMENT MARKET, BY ANIMAL TYPE, 2021-2030 (USD THOUSAND) 209
  • TABLE 242 SPAIN COMPANION ANIMAL IN VETERINARY PAIN MANAGEMENT MARKET, BY ANIMAL TYPE, 2021-2030 (USD THOUSAND) 209
  • TABLE 243 SPAIN PRODUCTION ANIMAL IN VETERINARY PAIN MANAGEMENT MARKET, BY ANIMAL TYPE, 2021-2030 (USD THOUSAND) 210
  • TABLE 244 SPAIN VETERINARY PAIN MANAGEMENT MARKET, BY PAIN SOURCE, 2021-2030 (USD THOUSAND) 210
  • TABLE 245 SPAIN VETERINARY PAIN MANAGEMENT MARKET, BY DOSAGE, 2021-2030 (USD THOUSAND) 210
  • TABLE 246 SPAIN SOLID IN VETERINARY PAIN MANAGEMENT MARKET, BY DOSAGE, 2021-2030 (USD THOUSAND) 211
  • TABLE 247 SPAIN LIQUID IN VETERINARY PAIN MANAGEMENT MARKET, BY DOSAGE, 2021-2030 (USD THOUSAND) 211
  • TABLE 248 SPAIN SEMI-SOLID IN VETERINARY PAIN MANAGEMENT MARKET, BY DOSAGE, 2021-2030 (USD THOUSAND) 211
  • TABLE 249 SPAIN VETERINARY PAIN MANAGEMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 212
  • TABLE 250 SPAIN VETERINARY PAIN MANAGEMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 212
  • TABLE 251 NETHERLANDS VETERINARY PAIN MANAGEMENT MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND) 213
  • TABLE 252 NETHERLANDS ANALGESICS IN VETERINARY PAIN MANAGEMENT MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND) 213
  • TABLE 253 NETHERLANDS ANTI-INFLAMMATORY (NSAIDS) IN VETERINARY PAIN MANAGEMENT MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND) 213
  • TABLE 254 NETHERLANDS OPIOIDS IN VETERINARY PAIN MANAGEMENT MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND) 214
  • TABLE 255 NETHERLANDS MU AGONISTS IN VETERINARY PAIN MANAGEMENT MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND) 214
  • TABLE 256 NETHERLANDS PARTIAL MU AGONIST IN VETERINARY PAIN MANAGEMENT MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND) 214
  • TABLE 257 NETHERLANDS KAPPA AGONIST-MU ANTAGONIST IN VETERINARY PAIN MANAGEMENT MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND) 215
  • TABLE 258 NETHERLANDS CORTECOSTERIODS IN VETERINARY PAIN MANAGEMENT MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND) 215
  • TABLE 259 NETHERLANDS VETERINARY PAIN MANAGEMENT MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND) 215
  • TABLE 260 NETHERLANDS VETERINARY PAIN MANAGEMENT MARKET, BY MODE OF PURCHASE, 2021-2030 (USD THOUSAND) 216
  • TABLE 261 NETHERLANDS VETERINARY PAIN MANAGEMENT MARKET, BY ANIMAL TYPE, 2021-2030 (USD THOUSAND) 216
  • TABLE 262 NETHERLANDS COMPANION ANIMAL IN VETERINARY PAIN MANAGEMENT MARKET, BY ANIMAL TYPE, 2021-2030 (USD THOUSAND) 216
  • TABLE 263 NETHERLANDS PRODUCTION ANIMAL IN VETERINARY PAIN MANAGEMENT MARKET, BY ANIMAL TYPE, 2021-2030 (USD THOUSAND) 217
  • TABLE 264 NETHERLANDS VETERINARY PAIN MANAGEMENT MARKET, BY PAIN SOURCE, 2021-2030 (USD THOUSAND) 217
  • TABLE 265 NETHERLANDS VETERINARY PAIN MANAGEMENT MARKET, BY DOSAGE, 2021-2030 (USD THOUSAND) 218
  • TABLE 266 NETHERLANDS SOLID IN VETERINARY PAIN MANAGEMENT MARKET, BY DOSAGE, 2021-2030 (USD THOUSAND) 218
  • TABLE 267 NETHERLANDS LIQUID IN VETERINARY PAIN MANAGEMENT MARKET, BY DOSAGE, 2021-2030 (USD THOUSAND) 218
  • TABLE 268 NETHERLANDS SEMI-SOLID IN VETERINARY PAIN MANAGEMENT MARKET, BY DOSAGE, 2021-2030 (USD THOUSAND) 219
  • TABLE 269 NETHERLANDS VETERINARY PAIN MANAGEMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 219
  • TABLE 270 NETHERLANDS VETERINARY PAIN MANAGEMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 219
  • TABLE 271 RUSSIA VETERINARY PAIN MANAGEMENT MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND) 220
  • TABLE 272 RUSSIA ANALGESICS IN VETERINARY PAIN MANAGEMENT MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND) 220
  • TABLE 273 RUSSIA ANTI-INFLAMMATORY (NSAIDS) IN VETERINARY PAIN MANAGEMENT MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND) 220
  • TABLE 274 RUSSIA OPIOIDS IN VETERINARY PAIN MANAGEMENT MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND) 221
  • TABLE 275 RUSSIA MU AGONISTS IN VETERINARY PAIN MANAGEMENT MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND) 221
  • TABLE 276 RUSSIA PARTIAL MU AGONIST IN VETERINARY PAIN MANAGEMENT MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND) 221
  • TABLE 277 RUSSIA KAPPA AGONIST-MU ANTAGONIST IN VETERINARY PAIN MANAGEMENT MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND) 222
  • TABLE 278 RUSSIA CORTECOSTERIODS IN VETERINARY PAIN MANAGEMENT MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND) 222
  • TABLE 279 RUSSIA VETERINARY PAIN MANAGEMENT MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND) 222
  • TABLE 280 RUSSIA VETERINARY PAIN MANAGEMENT MARKET, BY MODE OF PURCHASE, 2021-2030 (USD THOUSAND) 223
  • TABLE 281 RUSSIA VETERINARY PAIN MANAGEMENT MARKET, BY ANIMAL TYPE, 2021-2030 (USD THOUSAND) 223
  • TABLE 282 RUSSIA COMPANION ANIMAL IN VETERINARY PAIN MANAGEMENT MARKET, BY ANIMAL TYPE, 2021-2030 (USD THOUSAND) 223
  • TABLE 283 RUSSIA PRODUCTION ANIMAL IN VETERINARY PAIN MANAGEMENT MARKET, BY ANIMAL TYPE, 2021-2030 (USD THOUSAND) 224
  • TABLE 284 RUSSIA VETERINARY PAIN MANAGEMENT MARKET, BY PAIN SOURCE, 2021-2030 (USD THOUSAND) 224
  • TABLE 285 RUSSIA VETERINARY PAIN MANAGEMENT MARKET, BY DOSAGE, 2021-2030 (USD THOUSAND) 224
  • TABLE 286 RUSSIA SOLID IN VETERINARY PAIN MANAGEMENT MARKET, BY DOSAGE, 2021-2030 (USD THOUSAND) 225
  • TABLE 287 RUSSIA LIQUID IN VETERINARY PAIN MANAGEMENT MARKET, BY DOSAGE, 2021-2030 (USD THOUSAND) 225
  • TABLE 288 RUSSIA SEMI-SOLID IN VETERINARY PAIN MANAGEMENT MARKET, BY DOSAGE, 2021-2030 (USD THOUSAND) 225
  • TABLE 289 RUSSIA VETERINARY PAIN MANAGEMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 226
  • TABLE 290 RUSSIA VETERINARY PAIN MANAGEMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 226
  • TABLE 291 SWITZERLAND VETERINARY PAIN MANAGEMENT MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND) 227
  • TABLE 292 SWITZERLAND ANALGESICS IN VETERINARY PAIN MANAGEMENT MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND) 227
  • TABLE 293 SWITZERLAND ANTI-INFLAMMATORY (NSAIDS) IN VETERINARY PAIN MANAGEMENT MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND) 227
  • TABLE 294 SWITZERLAND OPIOIDS IN VETERINARY PAIN MANAGEMENT MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND) 228
  • TABLE 295 SWITZERLAND MU AGONISTS IN VETERINARY PAIN MANAGEMENT MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND) 228
  • TABLE 296 SWITZERLAND PARTIAL MU AGONIST IN VETERINARY PAIN MANAGEMENT MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND) 228
  • TABLE 297 SWITZERLAND KAPPA AGONIST-MU ANTAGONIST IN VETERINARY PAIN MANAGEMENT MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND) 229
  • TABLE 298 SWITZERLAND CORTECOSTERIODS IN VETERINARY PAIN MANAGEMENT MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND) 229
  • TABLE 299 SWITZERLAND VETERINARY PAIN MANAGEMENT MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND) 229
  • TABLE 300 SWITZERLAND VETERINARY PAIN MANAGEMENT MARKET, BY MODE OF PURCHASE, 2021-2030 (USD THOUSAND) 230
  • TABLE 301 SWITZERLAND VETERINARY PAIN MANAGEMENT MARKET, BY ANIMAL TYPE, 2021-2030 (USD THOUSAND) 230
  • TABLE 302 SWITZERLAND COMPANION ANIMAL IN VETERINARY PAIN MANAGEMENT MARKET, BY ANIMAL TYPE, 2021-2030 (USD THOUSAND) 230
  • TABLE 303 SWITZERLAND PRODUCTION ANIMAL IN VETERINARY PAIN MANAGEMENT MARKET, BY ANIMAL TYPE, 2021-2030 (USD THOUSAND) 231
  • TABLE 304 SWITZERLAND VETERINARY PAIN MANAGEMENT MARKET, BY PAIN SOURCE, 2021-2030 (USD THOUSAND) 231
  • TABLE 305 SWITZERLAND VETERINARY PAIN MANAGEMENT MARKET, BY DOSAGE, 2021-2030 (USD THOUSAND) 232
  • TABLE 306 SWITZERLAND SOLID IN VETERINARY PAIN MANAGEMENT MARKET, BY DOSAGE, 2021-2030 (USD THOUSAND) 232
  • TABLE 307 SWITZERLAND LIQUID IN VETERINARY PAIN MANAGEMENT MARKET, BY DOSAGE, 2021-2030 (USD THOUSAND) 232
  • TABLE 308 SWITZERLAND SEMI-SOLID IN VETERINARY PAIN MANAGEMENT MARKET, BY DOSAGE, 2021-2030 (USD THOUSAND) 233
  • TABLE 309 SWITZERLAND VETERINARY PAIN MANAGEMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 233
  • TABLE 310 SWITZERLAND VETERINARY PAIN MANAGEMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 233
  • TABLE 311 POLAND VETERINARY PAIN MANAGEMENT MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND) 234
  • TABLE 312 POLAND ANALGESICS IN VETERINARY PAIN MANAGEMENT MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND) 234
  • TABLE 313 POLAND ANTI-INFLAMMATORY (NSAIDS) IN VETERINARY PAIN MANAGEMENT MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND) 234
  • TABLE 314 POLAND OPIOIDS IN VETERINARY PAIN MANAGEMENT MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND) 235
  • TABLE 315 POLAND MU AGONISTS IN VETERINARY PAIN MANAGEMENT MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND) 235
  • TABLE 316 POLAND PARTIAL MU AGONIST IN VETERINARY PAIN MANAGEMENT MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND) 235
  • TABLE 317 POLAND KAPPA AGONIST-MU ANTAGONIST IN VETERINARY PAIN MANAGEMENT MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND) 236
  • TABLE 318 POLAND CORTECOSTERIODS IN VETERINARY PAIN MANAGEMENT MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND) 236
  • TABLE 319 POLAND VETERINARY PAIN MANAGEMENT MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND) 236
  • TABLE 320 POLAND VETERINARY PAIN MANAGEMENT MARKET, BY MODE OF PURCHASE, 2021-2030 (USD THOUSAND) 237
  • TABLE 321 POLAND VETERINARY PAIN MANAGEMENT MARKET, BY ANIMAL TYPE, 2021-2030 (USD THOUSAND) 237
  • TABLE 322 POLAND COMPANION ANIMAL IN VETERINARY PAIN MANAGEMENT MARKET, BY ANIMAL TYPE, 2021-2030 (USD THOUSAND) 237
  • TABLE 323 POLAND PRODUCTION ANIMAL IN VETERINARY PAIN MANAGEMENT MARKET, BY ANIMAL TYPE, 2021-2030 (USD THOUSAND) 238
  • TABLE 324 POLAND VETERINARY PAIN MANAGEMENT MARKET, BY PAIN SOURCE, 2021-2030 (USD THOUSAND) 238
  • TABLE 325 POLAND VETERINARY PAIN MANAGEMENT MARKET, BY DOSAGE, 2021-2030 (USD THOUSAND) 239
  • TABLE 326 POLAND SOLID IN VETERINARY PAIN MANAGEMENT MARKET, BY DOSAGE, 2021-2030 (USD THOUSAND) 239
  • TABLE 327 POLAND LIQUID IN VETERINARY PAIN MANAGEMENT MARKET, BY DOSAGE, 2021-2030 (USD THOUSAND) 239
  • TABLE 328 POLAND SEMI-SOLID IN VETERINARY PAIN MANAGEMENT MARKET, BY DOSAGE, 2021-2030 (USD THOUSAND) 240
  • TABLE 329 POLAND VETERINARY PAIN MANAGEMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 240
  • TABLE 330 POLAND VETERINARY PAIN MANAGEMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 240
  • TABLE 331 BELGIUM VETERINARY PAIN MANAGEMENT MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND) 241
  • TABLE 332 BELGIUM ANALGESICS IN VETERINARY PAIN MANAGEMENT MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND) 241
  • TABLE 333 BELGIUM ANTI-INFLAMMATORY (NSAIDS) IN VETERINARY PAIN MANAGEMENT MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND) 241
  • TABLE 334 BELGIUM OPIOIDS IN VETERINARY PAIN MANAGEMENT MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND) 242
  • TABLE 335 BELGIUM MU AGONISTS IN VETERINARY PAIN MANAGEMENT MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND) 242
  • TABLE 336 BELGIUM PARTIAL MU AGONIST IN VETERINARY PAIN MANAGEMENT MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND) 242
  • TABLE 337 BELGIUM KAPPA AGONIST-MU ANTAGONIST IN VETERINARY PAIN MANAGEMENT MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND) 243
  • TABLE 338 BELGIUM CORTECOSTERIODS IN VETERINARY PAIN MANAGEMENT MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND) 243
  • TABLE 339 BELGIUM VETERINARY PAIN MANAGEMENT MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND) 243
  • TABLE 340 BELGIUM VETERINARY PAIN MANAGEMENT MARKET, BY MODE OF PURCHASE, 2021-2030 (USD THOUSAND) 244
  • TABLE 341 BELGIUM VETERINARY PAIN MANAGEMENT MARKET, BY ANIMAL TYPE, 2021-2030 (USD THOUSAND) 244
  • TABLE 342 BELGIUM COMPANION ANIMAL IN VETERINARY PAIN MANAGEMENT MARKET, BY ANIMAL TYPE, 2021-2030 (USD THOUSAND) 244
  • TABLE 343 BELGIUM PRODUCTION ANIMAL IN VETERINARY PAIN MANAGEMENT MARKET, BY ANIMAL TYPE, 2021-2030 (USD THOUSAND) 245
  • TABLE 344 BELGIUM VETERINARY PAIN MANAGEMENT MARKET, BY PAIN SOURCE, 2021-2030 (USD THOUSAND) 245
  • TABLE 345 BELGIUM VETERINARY PAIN MANAGEMENT MARKET, BY DOSAGE, 2021-2030 (USD THOUSAND) 246
  • TABLE 346 BELGIUM SOLID IN VETERINARY PAIN MANAGEMENT MARKET, BY DOSAGE, 2021-2030 (USD THOUSAND) 246
  • TABLE 347 BELGIUM LIQUID IN VETERINARY PAIN MANAGEMENT MARKET, BY DOSAGE, 2021-2030 (USD THOUSAND) 246
  • TABLE 348 BELGIUM SEMI-SOLID IN VETERINARY PAIN MANAGEMENT MARKET, BY DOSAGE, 2021-2030 (USD THOUSAND) 247
  • TABLE 349 BELGIUM VETERINARY PAIN MANAGEMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 247
  • TABLE 350 BELGIUM VETERINARY PAIN MANAGEMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 247
  • TABLE 351 TURKEY VETERINARY PAIN MANAGEMENT MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND) 248
  • TABLE 352 TURKEY ANALGESICS IN VETERINARY PAIN MANAGEMENT MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND) 248
  • TABLE 353 TURKEY ANTI-INFLAMMATORY (NSAIDS) IN VETERINARY PAIN MANAGEMENT MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND) 248
  • TABLE 354 TURKEY OPIOIDS IN VETERINARY PAIN MANAGEMENT MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND) 249
  • TABLE 355 TURKEY MU AGONISTS IN VETERINARY PAIN MANAGEMENT MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND) 249
  • TABLE 356 TURKEY PARTIAL MU AGONIST IN VETERINARY PAIN MANAGEMENT MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND) 249
  • TABLE 357 TURKEY KAPPA AGONIST-MU ANTAGONIST IN VETERINARY PAIN MANAGEMENT MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND) 250
  • TABLE 358 TURKEY CORTECOSTERIODS IN VETERINARY PAIN MANAGEMENT MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND) 250
  • TABLE 359 TURKEY VETERINARY PAIN MANAGEMENT MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND) 250
  • TABLE 360 TURKEY VETERINARY PAIN MANAGEMENT MARKET, BY MODE OF PURCHASE, 2021-2030 (USD THOUSAND) 251
  • TABLE 361 TURKEY VETERINARY PAIN MANAGEMENT MARKET, BY ANIMAL TYPE, 2021-2030 (USD THOUSAND) 251
  • TABLE 362 TURKEY COMPANION ANIMAL IN VETERINARY PAIN MANAGEMENT MARKET, BY ANIMAL TYPE, 2021-2030 (USD THOUSAND) 251
  • TABLE 363 TURKEY PRODUCTION ANIMAL IN VETERINARY PAIN MANAGEMENT MARKET, BY ANIMAL TYPE, 2021-2030 (USD THOUSAND) 252
  • TABLE 364 TURKEY VETERINARY PAIN MANAGEMENT MARKET, BY PAIN SOURCE, 2021-2030 (USD THOUSAND) 252
  • TABLE 365 TURKEY VETERINARY PAIN MANAGEMENT MARKET, BY DOSAGE, 2021-2030 (USD THOUSAND) 252
  • TABLE 366 TURKEY SOLID IN VETERINARY PAIN MANAGEMENT MARKET, BY DOSAGE, 2021-2030 (USD THOUSAND) 253
  • TABLE 367 TURKEY LIQUID IN VETERINARY PAIN MANAGEMENT MARKET, BY DOSAGE, 2021-2030 (USD THOUSAND) 253
  • TABLE 368 TURKEY SEMI-SOLID IN VETERINARY PAIN MANAGEMENT MARKET, BY DOSAGE, 2021-2030 (USD THOUSAND) 253
  • TABLE 369 TURKEY VETERINARY PAIN MANAGEMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 254
  • TABLE 370 TURKEY VETERINARY PAIN MANAGEMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 254
  • TABLE 371 SWEDEN VETERINARY PAIN MANAGEMENT MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND) 255
  • TABLE 372 SWEDEN ANALGESICS IN VETERINARY PAIN MANAGEMENT MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND) 255
  • TABLE 373 SWEDEN ANTI-INFLAMMATORY (NSAIDS) IN VETERINARY PAIN MANAGEMENT MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND) 255
  • TABLE 374 SWEDEN OPIOIDS IN VETERINARY PAIN MANAGEMENT MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND) 256
  • TABLE 375 SWEDEN MU AGONISTS IN VETERINARY PAIN MANAGEMENT MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND) 256
  • TABLE 376 SWEDEN PARTIAL MU AGONIST IN VETERINARY PAIN MANAGEMENT MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND) 256
  • TABLE 377 SWEDEN KAPPA AGONIST-MU ANTAGONIST IN VETERINARY PAIN MANAGEMENT MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND) 257
  • TABLE 378 SWEDEN CORTECOSTERIODS IN VETERINARY PAIN MANAGEMENT MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND) 257
  • TABLE 379 SWEDEN VETERINARY PAIN MANAGEMENT MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND) 257
  • TABLE 380 SWEDEN VETERINARY PAIN MANAGEMENT MARKET, BY MODE OF PURCHASE, 2021-2030 (USD THOUSAND) 258
  • TABLE 381 SWEDEN VETERINARY PAIN MANAGEMENT MARKET, BY ANIMAL TYPE, 2021-2030 (USD THOUSAND) 258
  • TABLE 382 SWEDEN COMPANION ANIMAL IN VETERINARY PAIN MANAGEMENT MARKET, BY ANIMAL TYPE, 2021-2030 (USD THOUSAND) 258
  • TABLE 383 SWEDEN PRODUCTION ANIMAL IN VETERINARY PAIN MANAGEMENT MARKET, BY ANIMAL TYPE, 2021-2030 (USD THOUSAND) 259
  • TABLE 384 SWEDEN VETERINARY PAIN MANAGEMENT MARKET, BY PAIN SOURCE, 2021-2030 (USD THOUSAND) 259
  • TABLE 385 SWEDEN VETERINARY PAIN MANAGEMENT MARKET, BY DOSAGE, 2021-2030 (USD THOUSAND) 259
  • TABLE 386 SWEDEN SOLID IN VETERINARY PAIN MANAGEMENT MARKET, BY DOSAGE, 2021-2030 (USD THOUSAND) 260
  • TABLE 387 SWEDEN LIQUID IN VETERINARY PAIN MANAGEMENT MARKET, BY DOSAGE, 2021-2030 (USD THOUSAND) 260
  • TABLE 388 SWEDEN SEMI-SOLID IN VETERINARY PAIN MANAGEMENT MARKET, BY DOSAGE, 2021-2030 (USD THOUSAND) 260
  • TABLE 389 SWEDEN VETERINARY PAIN MANAGEMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 261
  • TABLE 390 SWEDEN VETERINARY PAIN MANAGEMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 261
  • TABLE 391 DENMARK VETERINARY PAIN MANAGEMENT MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND) 262
  • TABLE 392 DENMARK ANALGESICS IN VETERINARY PAIN MANAGEMENT MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND) 262
  • TABLE 393 DENMARK ANTI-INFLAMMATORY (NSAIDS) IN VETERINARY PAIN MANAGEMENT MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND) 262
  • TABLE 394 DENMARK OPIOIDS IN VETERINARY PAIN MANAGEMENT MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND) 263
  • TABLE 395 DENMARK MU AGONISTS IN VETERINARY PAIN MANAGEMENT MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND) 263
  • TABLE 396 DENMARK PARTIAL MU AGONIST IN VETERINARY PAIN MANAGEMENT MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND) 263
  • TABLE 397 DENMARK KAPPA AGONIST-MU ANTAGONIST IN VETERINARY PAIN MANAGEMENT MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND) 264
  • TABLE 398 DENMARK CORTECOSTERIODS IN VETERINARY PAIN MANAGEMENT MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND) 264
  • TABLE 399 DENMARK VETERINARY PAIN MANAGEMENT MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND) 264
  • TABLE 400 DENMARK VETERINARY PAIN MANAGEMENT MARKET, BY MODE OF PURCHASE, 2021-2030 (USD THOUSAND) 265

LIST OF FIGURES

  • FIGURE 1 GLOBAL VETERINARY PAIN MANAGEMENT MARKET: SEGMENTATION 67
  • FIGURE 2 GLOBAL VETERINARY PAIN MANAGEMENT MARKET: DATA TRIANGULATION 70
  • FIGURE 3 GLOBAL VETERINARY PAIN MANAGEMENT MARKET: DROC ANALYSIS 71
  • FIGURE 4 GLOBAL VETERINARY PAIN MANAGEMENT MARKET: GLOBAL VS REGIONAL MARKET ANALYSIS 72
  • FIGURE 5 GLOBAL VETERINARY PAIN MANAGEMENT MARKET: COMPANY RESEARCH ANALYSIS 72
  • FIGURE 6 GLOBAL VETERINARY PAIN MANAGEMENT MARKET: INTERVIEW DEMOGRAPHICS 73
  • FIGURE 7 GLOBAL VETERINARY PAIN MANAGEMENT MARKET: MARKET END USER COVERAGE GRID 74
  • FIGURE 8 GLOBAL VETERINARY PAIN MANAGEMENT MARKET: DBMR MARKET POSITION GRID 76
  • FIGURE 9 GLOBAL VETERINARY PAIN MANAGEMENT MARKET: VENDOR SHARE ANALYSIS 77
  • FIGURE 10 GLOBAL VETERINARY PAIN MANAGEMENT MARKET: SEGMENTATION 81
  • FIGURE 11 INCREASING PET OWNERSHIP AND ADVANCEMENTS IN VETERINARY MEDICINE ARE EXPECTED TO DRIVE THE GROWTH OF THE GLOBAL VETERINARY PAIN MANAGEMENT MARKET FROM 2023 TO 2030 82
  • FIGURE 12 THE ANALGESICS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE GLOBAL VETERINARY PAIN MANAGEMENT MARKET IN 2023 & 2030 82
  • FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES FOR GLOBAL VETERINARY PAIN MANAGEMENT MARKET 87
  • FIGURE 14 GLOBAL VETERINARY PAIN MANAGEMENT MARKET: BY PRODUCT TYPE, 2022 95
  • FIGURE 15 GLOBAL VETERINARY PAIN MANAGEMENT MARKET: BY DRUG TYPE, 2022 104
  • FIGURE 16 GLOBAL VETERINARY PAIN MANAGEMENT MARKET: BY MODE OF PURCHASE, 2022 107
  • FIGURE 17 GLOBAL VETERINARY PAIN MANAGEMENT MARKET: BY ANIMAL TYPE, 2022 110
  • FIGURE 18 GLOBAL VETERINARY PAIN MANAGEMENT MARKET: BY PAIN SOURCE, 2022 115
  • FIGURE 19 GLOBAL VETERINARY PAIN MANAGEMENT MARKET: BY DOSAGE, 2022 120
  • FIGURE 20 GLOBAL VETERINARY PAIN MANAGEMENT MARKET: BY ROUTE OF ADMINISTRATION, 2022 126
  • FIGURE 21 GLOBAL VETERINARY PAIN MANAGEMENT MARKET: BY END USER, 2022 130
  • FIGURE 22 GLOBAL VETERINARY PAIN MANAGEMENT MARKET: SNAPSHOT (2022) 137
  • FIGURE 23 GLOBAL VETERINARY PAIN MANAGEMENT MARKET: COMPANY SHARE 2022 (%) 485
  • FIGURE 24 NORTH AMERICA VETERINARY PAIN MANAGEMENT MARKET: COMPANY SHARE 2022 (%) 486
  • FIGURE 25 EUROPE VETERINARY PAIN MANAGEMENT MARKET: COMPANY SHARE 2022 (%) 487
  • FIGURE 26 ASIA-PACIFIC VETERINARY PAIN MANAGEMENT MARKET: COMPANY SHARE 2022 (%) 488
目次

Global veterinary pain management market is expected to reach USD 3,287,278.56 thousand by 2030 from USD 2,151,103.97 thousand in 2022 growing at the CAGR of 5.6% in the forecast period of 2023 to 2030. The new market report contains data for the historic year 2021, the base year of calculation is 2022 and the forecast period is 2023 to 2030.

Market Segmentation

Global Veterinary Pain Management Market, By Product Type (Analgesics, Corticosteroids, and Alpha 2 Agonists), Drug Type (Branded and Generic), Mode of Purchase (Prescription Based and OTC), Animal Type (Companion Animal and Production Animal), Pain Source (Chronic Pain, Acute Pain, Post-Operative Pain, and Dental Pain), Dosage (Solid, Liquid, and Semi-Solid), Route of Administration (Parenteral, Oral, and Topical), End User (Veterinary Hospitals, Veterinary Clinics, Pet Shops, Animal Farms, Academic & Research Institutes, and Others), Country (U.S., Canada, Mexico, Germany, France, U.K., Italy, Russia, Spain, Netherlands, Switzerland, Belgium, Turkey, Poland, Denmark, Sweden, Norwat, Funland, rest of Europe, China, Japan, India, Australia, South Korea, Singapore, Malaysia, Thailand, Indonesia, Philippines, Taiwan, Vietnam, rest of Asia-Pacific, South Africa, Saudi Arabi, U.A.E., Egypt, Israel, Kuwait, Oman, Qatar, Bahrain, rest of Middle East and Africa, Brazil, Argentina, and rest of South America) - Industry Trends and Forecast to 2030.

Overview of Global Veterinary Pain Management Market Dynamics

  • Driver
  • Rising incidences of pet diseases
  • Restraint
  • High costs of pet care
  • Opportunity
  • Technological advancements for pain management

Market Players

Some of the major market players operating in the global veterinary pain management market are:

  • Dechra Pharmaceuticals PLC
  • Virbac
  • Norbrook
  • Durvet Animal Health Products
  • Bimeda, Inc.
  • Inovet ( A subsidiary of Orion Group)
  • Chanelle Pharma
  • Vetoquinol
  • Elanco
  • Merck & Co., Inc.
  • Zoetis Services LLC
  • Ceva Animal Health, LLC

TABLE OF CONTENTS

1 INTRODUCTION 61

  • 1.1 OBJECTIVES OF THE STUDY 61
  • 1.2 MARKET DEFINITION 61
  • 1.3 OVERVIEW OF THE GLOBAL VETERINARY PAIN MANAGEMENT MARKET 61
  • 1.4 CURRENCY AND PRICING 63
  • 1.5 LIMITATIONS 63
  • 1.6 MARKETS COVERED 64

2 MARKET SEGMENTATION 67

  • 2.1 MARKETS COVERED 67
  • 2.2 GEOGRAPHICAL SCOPE 68
  • 2.3 YEARS CONSIDERED FOR THE STUDY 69
  • 2.4 DBMR TRIPOD DATA VALIDATION MODEL 70
  • 2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 73
  • 2.6 MULTIVARIATE MODELLING 74
  • 2.7 MARKET END USER COVERAGE GRID 74
  • 2.8 PRODUCT LIFELINE CURVE 75
  • 2.9 DBMR MARKET POSITION GRID 76
  • 2.10 VENDOR SHARE ANALYSIS 77
  • 2.11 SECONDARY SOURCES 78
  • 2.12 ASSUMPTIONS 78

3 EXECUTIVE SUMMARY 79

4 PREMIUM INSIGHTS 82

  • 4.1 PESTEL ANALYSIS 83
  • 4.2 PORTER'S FIVE FORCES 84
  • 4.3 BRAND REVENUE ANALYSIS 85

5 MARKET OVERVIEW 86

  • 5.1 DRIVERS 88
    • 5.1.1 INCREASING PET OWNERSHIP 88
    • 5.1.2 ADVANCEMENTS IN VETERINARY MEDICINE 88
    • 5.1.3 GROWING INCIDENCES OF PET DISEASES 89
    • 5.1.4 INCREASED GOVERNMENT PROJECTS TO ENHANCE ANIMAL CARE 89
  • 5.2 RESTRAINTS 90
    • 5.2.1 INCREASING PET CARE COSTS 90
    • 5.2.2 STRICT REGULATORY GUIDELINES 90 
  • 5.3 OPPORTUNITIES 91
    • 5.3.1 RISING R&D ACTIVITIES AND PRODUCT APPROVAL FOR VETERINARY PAIN MANAGEMENT 91
    • 5.3.2 RISING POPULARITY OF NON- CONVENTIONAL TREATMENT APPROACHES 92
    • 5.3.3 TECHNOLOGICAL ADVANCEMENTS 92
  • 5.4 CHALLENGES 93
    • 5.4.1 LIMITED AVAILABILITY OF VETERINARIANS 93
    • 5.4.2 RESISTANCE TO MEDICATIONS 93

6 GLOBAL VETERINARY PAIN MANAGEMENT MARKET, BY PRODUCT TYPE 94

  • 6.1 OVERVIEW 95
  • 6.2 ANALGESICS 96
    • 6.2.1 ANTI- INFLAMMATORY (NSAIDS) 96
      • 6.2.1.1 CARPROFEN 97
      • 6.2.1.2 MELOXICAM 97
      • 6.2.1.3 PHENYLBUTAZONE 97
      • 6.2.1.4 ACETAMINOPHEN 97
      • 6.2.1.5 FIROCOXIB 97
      • 6.2.1.6 DERACOXIB 97
      • 6.2.1.7 OTHERS 98
    • 6.2.2 OPIOIDS 98
      • 6.2.2.1 MU AGONISTS 98
        • 6.2.2.1.1 METHADONE 99
        • 6.2.2.1.2 MEPERIDINE 99
        • 6.2.2.1.3 MORPHINE 99
        • 6.2.2.1.4 OXYMORPHONE 99
        • 6.2.2.1.5 OTHERS 99
      • 6.2.2.2 PARTIAL MU AGONIST 99
        • 6.2.2.2.1 BUPRENORPHINE 99
        • 6.2.2.2.2 OTHERS 100
      • 6.2.2.3 KAPPA AGONIST MU ANTAGONIST 100
        • 6.2.2.3.1 BUTORPHANOL 100
        • 6.2.2.3.2 OTHERS 100
  • 6.3 CORTICOSTEROIDS 101
    • 6.3.1 DEXAMETHASONE 101
    • 6.3.2 PREDNISOLONE 101
    • 6.3.3 PREDNISONE 101
    • 6.3.4 OTHERS 102
  • 6.4 ALPHA 2 AGONISTS 102 

7 GLOBAL VETERINARY PAIN MANAGEMENT MARKET, BY DRUG TYPE 103

  • 7.1 OVERVIEW 104
  • 7.2 BRANDED 105
  • 7.3 GENERIC 105

8 GLOBAL VETERINARY PAIN MANAGEMENT MARKET, BY MODE OF PURCHASE 106

  • 8.1 OVERVIEW 107
  • 8.2 PRESCRIPTION BASED 108
  • 8.3 OTC 108

9 GLOBAL VETERINARY PAIN MANAGEMENT MARKET, BY ANIMAL TYPE 109

  • 9.1 OVERVIEW 110
  • 9.2 COMPANION ANIMAL 111
    • 9.2.1 CANINE 112
    • 9.2.2 EQUINE 112
    • 9.2.3 FELINE 112
    • 9.2.4 OTHERS 112
  • 9.3 PRODUCTION ANIMAL 112
    • 9.3.1 CATTLE 113
    • 9.3.2 SWINE 113
    • 9.3.3 POULTRY 113
    • 9.3.4 FISH 113
    • 9.3.5 OTHERS 113

10 GLOBAL VETERINARY PAIN MANAGEMENT MARKET, BY PAIN SOURCE 114

  • 10.1 OVERVIEW 115
  • 10.2 CHRONIC PAIN 116
  • 10.3 ACUTE PAIN 117
  • 10.4 POST OPERATIVE PAIN 117
  • 10.5 DENTAL PAIN 118

11 GLOBAL VETERINARY PAIN MANAGEMENT MARKET, BY DOSAGE 119

  • 11.1 OVERVIEW 120
  • 11.2 SOLID 121
    • 11.2.1 TABLET 121
    • 11.2.2 POWDER 122
    • 11.2.3 OTHERS 122
  • 11.3 LIQUID 122
    • 11.3.1 SOLUTION 122
    • 11.3.2 SYRUP 123
    • 11.3.3 SUSPENSION 123
    • 11.3.4 OTHERS 123
  • 11.4 SEMI SOLID 123
    • 11.4.1 GEL 124
    • 11.4.2 CREAM 124
    • 11.4.3 OTHERS 124

12 GLOBAL VETERINARY PAIN MANAGEMENT MARKET, BY ROUTE OF ADMINISTRATION 125

  • 12.1 OVERVIEW 126
  • 12.2 PARENTERAL 127
  • 12.3 ORAL 128
  • 12.4 TOPICAL 128

13 GLOBAL VETERINARY PAIN MANAGEMENT MARKET, BY END USER 129

  • 13.1 OVERVIEW 130
  • 13.2 VETERINARY HOSPITALS 131
  • 13.3 VETERINARY CLINICS 132
  • 13.4 PET SHOPS 132
  • 13.5 ANIMAL FARMS 133
  • 13.6 ACADEMIC & RESEARCH INSTITUTES 133
  • 13.7 OTHERS 134

14 GLOBAL VETERINARY PAIN MANAGEMENT MARKET, BY GEOGRAPHY 135

  • 14.1 OVERVIEW 136
  • 14.2 NORTH AMERICA 140
    • 14.2.1 U.S. 148
    • 14.2.2 CANADA 155
    • 14.2.3 MEXICO 163
  • 14.3 EUROPE 170
    • 14.3.1 GERMANY 178
    • 14.3.2 FRANCE 185
    • 14.3.3 U K 192
    • 14.3.4 ITALY 199
    • 14.3.5 SPAIN 206
    • 14.3.6 NETHERLANDS 213
    • 14.3.7 RUSSIA 220
    • 14.3.8 SWITZERLAND 227
    • 14.3.9 POLAND 234
    • 14.3.10 BELGIUM 241
    • 14.3.11 TURKEY 248
    • 14.3.12 SWEDEN 255
    • 14.3.13 DENMARK 262
    • 14.3.14 NORWAY 269
    • 14.3.15 FINLAND 276
    • 14.3.16 REST OF EUROPE 283
  • 14.4 ASIA PACIFIC 290
    • 14.4.1 CHINA 298
    • 14.4.2 AUSTRALIA 305
    • 14.4.3 INDIA 312
    • 14.4.4 JAPAN 319
    • 14.4.5 SINGAPORE 326
    • 14.4.6 INDONESIA 333
    • 14.4.7 MALAYSIA 340
    • 14.4.8 NEW ZEALAND 347
    • 14.4.9 SOUTH KOREA 354
    • 14.4.10 VIETNAM 361
    • 14.4.11 THAILAND 368
    • 14.4.12 PHILIPPINES 375
    • 14.4.13 TAIWAN 382
    • 14.4.14 REST OF ASIA-PACIFIC 389
  • 14.5 SOUTH AMERICA 390
    • 14.5.1 BRAZIL 398
    • 14.5.2 ARGENTINA 405
    • 14.5.3 REST OF SOUTH AMERICA 412
  • 14.6 MIDDLE EAST AND AFRICA 413
    • 14.6.1 SOUTH AFRICA 421
    • 14.6.2 SAUDI ARABIA 428
    • 14.6.3 U.A.E. 435
    • 14.6.4 EGYPT 442
    • 14.6.5 ISRAEL 449
    • 14.6.6 KUWAIT 456
    • 14.6.7 OMAN 463
    • 14.6.8 QATAR 470
    • 14.6.9 BAHRAIN 477
    • 14.6.10 REST OF MIDDLE EAST AND AFRICA 484

15 GLOBAL VETERINARY PAIN MANAGEMENT MARKET, COMPANY LANDSCAPE 485

  • 15.1 COMPANY SHARE ANALYSIS: GLOBAL 485
  • 15.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 486
  • 15.3 COMPANY SHARE ANALYSIS: EUROPE 487
  • 15.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 488

16 SWOT ANALYSIS 489

17 COMPANY PROFILE 490

  • 17.1 ZOETIS SERVICES LLC 490
    • 17.1.1 COMPANY SNAPSHOT 490
    • 17.1.2 COMPANY SHARE ANALYSIS 490
    • 17.1.3 PRODUCT PORTFOLIO 491
    • 17.1.4 RECENT DEVELOPMENTS 491
  • 17.2 ELANCO 492
    • 17.2.1 COMPANY SNAPSHOT 492
    • 17.2.2 REVENUE ANALYSIS 492
    • 17.2.3 COMPANY SHARE ANALYSIS 493
    • 17.2.4 PRODUCT PORTFOLIO 493
    • 17.2.5 RECENT DEVELOPMENT 493
  • 17.3 MERCK & CO., INC. 494
    • 17.3.1 COMPANY SNAPSHOT 494
    • 17.3.2 REVENUE ANALYSIS 494
    • 17.3.3 COMPANY SHARE ANALYSIS 495
    • 17.3.4 PRODUCT PORTFOLIO 495
    • 17.3.5 RECENT DEVELOPMENT 495
  • 17.4 BOEHRINGER INGELHEIM INTERNATIONAL GMBH 496
    • 17.4.1 COMPANY SNAPSHOT 496
    • 17.4.2 COMPANY SHARE ANALYSIS 496
    • 17.4.3 PRODUCT PORTFOLIO 497
    • 17.4.4 RECENT DEVELOPMENT 497
  • 17.5 VETOQUINOL 498
    • 17.5.1 COMPANY SNAPSHOT 498
    • 17.5.2 REVENUE ANALYSIS 498
    • 17.5.3 COMPANY SHARE ANALYSIS 499
    • 17.5.4 PRODUCT PORTFOLIO 499
    • 17.5.5 RECENT DEVELOPMENTS 499
  • 17.6 BIMEDA, INC. 501
    • 17.6.1 COMPANY SNAPSHOT 501
    • 17.6.2 PRODUCT PORTFOLIO 501
    • 17.6.3 RECENT DEVELOPMENT 501
  • 17.7 CEVA ANIMAL HEALTH, LLC 502
    • 17.7.1 COMPANY SNAPSHOT 502
    • 17.7.2 PRODUCT PORTFOLIO 502
    • 17.7.3 RECENT DEVELOPMENT 502
  • 17.8 CHANELLE PHARMA 503
    • 17.8.1 COMPANY SNAPSHOT 503
    • 17.8.2 PRODUCT PORTFOLIO 503
    • 17.8.3 RECENT DEVELOPMENT 503
  • 17.9 DECHRA PHARMACEUTICALS PLC 504
    • 17.9.1 COMPANY SNAPSHOT 504
    • 17.9.2 REVENUE ANALYSIS 504
    • 17.9.3 PRODUCT PORTFOLIO 505
    • 17.9.4 RECENT DEVELOPMENTS 505
  • 17.10 DURVET ANIMAL HEALTH PRODUCTS 506
    • 17.10.1 COMPANY SNAPSHOT 506
    • 17.10.2 PRODUCT PORTFOLIO 506
    • 17.10.3 RECENT DEVELOPMENT 506
  • 17.11 INOVET (A SUBSIDIARY OF ORION GROUP) 507
    • 17.11.1 COMPANY SNAPSHOT 507
    • 17.11.2 PRODUCT PORTFOLIO 507
    • 17.11.3 RECENT DEVELOPMENTS 507
  • 17.12 NORBROOK 509
    • 17.12.1 COMPANY SNAPSHOT 509
    • 17.12.2 PRODUCT PORTFOLIO 509
    • 17.12.3 RECENT DEVELOPMENT 509
  • 17.13 VIRBAC 510
    • 17.13.1 COMPANY SNAPSHOT 510
    • 17.13.2 REVENUE ANALYSIS 510
    • 17.13.3 PRODUCT PORTFOLIO 511
    • 17.13.4 RECENT DEVELOPMENT 511

18 QUESTIONNAIRE 512

19 RELATED REPORTS 516